Table 4 Effects of genetic risk scores and CSF biomarkers on longitudinal cognitive changes in PD patients.
From: Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease
Visuospatial | Memory | Semantic fluency | Frontal/executive | ||||||
---|---|---|---|---|---|---|---|---|---|
Predictors | β (SE) | P | β (SE) | P | β (SE) | P | β (SE) | P | |
Model 1 | GRS-AD | −0.46 (0.14) | 0.001* | −0.20 (0.16) | 0.210 | −0.12 (0.74) | 0.877 | −0.25 (0.59) | 0.679 |
GRS-PD | 0.12 (0.12) | 0.344 | 0.10 (0.15) | 0.516 | 2.14 (0.70) | 0.002* | 0.79 (0.55) | 0.150 | |
GRS-AD*GRS-PD | 0.57 (0.17) | 0.001* | |||||||
time | −0.05 (0.02) | 0.033 | −0.03 (0.03) | 0.284 | −0.26 (0.11) | 0.018 | −0.60 (0.11) | <0.001* | |
GRS-AD*time | −0.07 (0.03) | 0.037 | −0.03 (0.04) | 0.532 | −0.25 (0.15) | 0.111 | −0.37 (0.15) | 0.015 | |
GRS-PD*time | 0.03 (0.03) | 0.376 | 0.05 (0.04) | 0.214 | 0.07 (0.14) | 0.611 | 0.43 (0.14) | 0.002* | |
Model 2 | GRS-AD | −0.50 (0.15) | 0.001* | −0.20 (0.18) | 0.268 | 0.04 (0.84) | 0.965 | −0.20 (0.65) | 0.755 |
GRS-PD | 0.11 (0.13) | 0.417 | 0.24 (0.16) | 0.132 | 2.47 (0.76) | 0.001* | 0.96 (0.58) | 0.100 | |
GRS-AD*GRS-PD | 0.52 (0.18) | 0.004 | |||||||
time | −0.0004 (0.07) | 0.996 | 0.23 (0.09) | 0.009 | 0.54 (0.32) | 0.098 | 0.23 (0.32) | 0.476 | |
GRS-AD*time | −0.05 (0.04) | 0.155 | 0.04 (0.05) | 0.383 | −0.09 (0.16) | 0.592 | −0.15 (0.16) | 0.357 | |
GRS-PD*time | 0.03 (0.03) | 0.287 | 0.05 (0.04) | 0.257 | −0.009 (0.146) | 0.948 | 0.47 (0.15) | 0.001* | |
Baseline p-tau/Aβ42 | −0.004 (0.01) | 0.694 | 0.003 (0.01) | 0.787 | −0.07 (0.06) | 0.245 | −0.02 (0.05) | 0.612 | |
Baseline αSyn | −0.05 (0.14) | 0.743 | 0.09 (0.18) | 0.609 | 0.24 (0.84) | 0.776 | 1.14 (0.64) | 0.074 | |
Baseline p-tau/Aβ42*time | −0.005 (0.003) | 0.082 | −0.02 (0.003) | <0.001* | −0.05 (0.01) | <0.001* | −0.07 (0.01) | <0.001* | |
Baseline αSyn*time | 0.01 (0.04) | 0.700 | 0.02 (0.04) | 0.599 | 0.04 (0.16) | 0.799 | 0.18 (0.16) | 0.274 |